OCT 16, 2013 2:00 PM PDT

PSA Screening and Early Detection for Prostate Cancer 2013: Controversy and Opportunity

C.E. Credits: CE
Speaker
  • James H Semans MD Professor of Surgery, Division of Urologic Surgery, Director, Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center
    BIOGRAPHY

Abstract

While the Prostate Specific Antigen (PSA) blood test has been available since 1986 and FDA-approved for the early detection of prostate cancer since the early 1990s, 2012 marked a critical inflection point when the US Preventative Services Task Force (USPSTF) gave PSA a D-rating and generally discouraged its use. This D-rating was based on one randomized controlled trial (RCT) that showed no survival benefit to screening and another RCT that showed a survival benefit but at the cost of over-detection of non-life-threatening tumors. Despite the USPSTF, the PSA test remains widely used and many experts feel that the PSA test is still valuable when used in a more intelligent way. In using PSA more effectively, the American Urological Association (AUA) and the National Comprehensive Cancer Network (NCCN) suggest that all men have a baseline PSA test at age 40 to assess their future risk of prostate cancer. Using this baseline along with changes over time in the form of PSA Velocity (PSAV) or PSA Doubling Time (PSA-DT) can help doctors pick of prostate cancer in young men where finding cancers is more relevant. Further ways to use PSA smarter include age-adjusting PSA levels to increase detection of important cancers in young men while avoiding detection of non-life threatening cancers in older men. Taking into account other high risk features such as family history and race/ethnicity can fine tune early detection efforts. In addition to using total PSA, other PSA tools include the percent free PSA, complexed PSA, and the urine-based molecular marker, PCA-3 can further improve the accuracy of prostate cancer early detection efforts. Finally, if a prostate cancer is detected, better risk stratification can help doctors decide if a patient requires active treatment with surgery or radiation or active surveillance.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
DEC 09, 2021 11:00 AM PST
C.E. CREDITS
DEC 09, 2021 11:00 AM PST
Date: December 09, 2021 Time: 11:00am (PDT), 2:00pm (EDT) The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the need for new...
OCT 12, 2021 9:00 AM PDT
C.E. CREDITS
OCT 12, 2021 9:00 AM PDT
Date: October 12, 2021 Time: 9:00am (PDT), 12:00pm (EDT) SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization o...
OCT 16, 2013 2:00 PM PDT

PSA Screening and Early Detection for Prostate Cancer 2013: Controversy and Opportunity

C.E. Credits: CE


Show Resources
Loading Comments...
Show Resources